FARN vs. GNS, ONT, ERGO, SLN, PRTC, HZD, OXB, VRP, ARIX, and 4BB
Should you be buying Faron Pharmaceuticals Oy stock or one of its competitors? The main competitors of Faron Pharmaceuticals Oy include Genus (GNS), Oxford Nanopore Technologies (ONT), Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Oxford Biomedica (OXB), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), and 4basebio (4BB). These companies are all part of the "biotechnology" industry.
Faron Pharmaceuticals Oy vs.
Genus (LON:GNS) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, community ranking, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.
Genus has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Faron Pharmaceuticals Oy has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500.
Genus received 35 more outperform votes than Faron Pharmaceuticals Oy when rated by MarketBeat users. However, 77.51% of users gave Faron Pharmaceuticals Oy an outperform vote while only 70.54% of users gave Genus an outperform vote.
Genus has a net margin of 1.18% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Genus' return on equity of 1.41% beat Faron Pharmaceuticals Oy's return on equity.
77.8% of Genus shares are owned by institutional investors. Comparatively, 10.7% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 0.8% of Genus shares are owned by company insiders. Comparatively, 31.8% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Faron Pharmaceuticals Oy had 2 more articles in the media than Genus. MarketBeat recorded 2 mentions for Faron Pharmaceuticals Oy and 0 mentions for Genus. Faron Pharmaceuticals Oy's average media sentiment score of 0.37 beat Genus' score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.
Genus has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.
Genus presently has a consensus target price of GBX 2,150, indicating a potential upside of 32.88%. Given Genus' stronger consensus rating and higher probable upside, analysts plainly believe Genus is more favorable than Faron Pharmaceuticals Oy.
Summary
Genus beats Faron Pharmaceuticals Oy on 13 of the 17 factors compared between the two stocks.
Get Faron Pharmaceuticals Oy News Delivered to You Automatically
Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Faron Pharmaceuticals Oy Competitors List
Related Companies and Tools
This page (LON:FARN) was last updated on 4/17/2025 by MarketBeat.com Staff
Buy FARN Stock Free FARN Stock Alerts